breast cancer at esmo 2020: cdk4/6 inhibitors and checkpoint inhibitors
Published 3 years ago • 144 plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
21:47
esmo daily reporter talk: the role of cdk4/6 inhibitors in the early stage of #breastcancer.
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
8:04
key takeaways from esmo: cdk4/6 inhibitors for metastatic hr /her2- breast cancer
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
1:07
sequencing first-line cdk4/6 inhibitors in metastatic breast cancer
-
0:36
endocrine therapy and cdk4/6 inhibitors in high-risk hr breast cancer
-
8:30
cdk4/6 inhibitors in er metastatic breast cancer during the covid-19 pandemic
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
18:38
breast cancer esmo 2024 highlights: key studies discussed natalee, keynote 522, destiny-breast12
-
2:31
cdk4/6 inhibitors: a hot topic in breast cancer treatment